BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38677763)

  • 1. CX-4945 (Silmitasertib) Induces Cell Death by Impairing Lysosomal Utilization in
    Lee DS; Han MW; Kang Y; Kim C; Lee S; Kim KP; Yoo C
    Anticancer Res; 2024 May; 44(5):1939-1946. PubMed ID: 38677763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Casein Kinase 2 Inhibitor CX-4945 Promotes Cholangiocarcinoma Cell Death Through PLK1.
    Lee DS; Lee S; Kim C; Kim D; Kim KP; Yoo C
    Anticancer Res; 2022 Jul; 42(7):3435-3443. PubMed ID: 35790285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Growth, Anti-Angiogenic, and Pro-Apoptotic Effects by CX-4945, an Inhibitor of Casein Kinase 2, on HuCCT-1 Human Cholangiocarcinoma Cells via Control of Caspase-9/3, DR-4, STAT-3/STAT-5, Mcl-1, eIF-2α, and HIF-1α.
    Wang S; Yadav AK; Han JY; Ahn KS; Jang BC
    Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35683032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CK2 inhibition with silmitasertib promotes methuosis-like cell death associated to catastrophic massive vacuolization of colorectal cancer cells.
    Silva-Pavez E; Villar P; Trigo C; Caamaño E; Niechi I; Pérez P; Muñoz JP; Aguayo F; Burzio VA; Varas-Godoy M; Castro AF; Colombo MI; Tapia JC
    Cell Death Dis; 2019 Jan; 10(2):73. PubMed ID: 30683840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.
    Ma Y; Sender S; Sekora A; Kong W; Bauer P; Ameziane N; Krake S; Radefeldt M; Al-Ali R; Weiss FU; Lerch MM; Parveen A; Zechner D; Junghanss C; Murua Escobar H
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disruption of endocytic trafficking protein Rab7 impairs invasiveness of cholangiocarcinoma cells.
    Suwandittakul N; Reamtong O; Molee P; Maneewatchararangsri S; Sutherat M; Chaisri U; Wongkham S; Adisakwattana P
    Cancer Biomark; 2017 Sep; 20(3):255-266. PubMed ID: 28946560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Janus" efficacy of CX-5011: CK2 inhibition and methuosis induction by independent mechanisms.
    D'Amore C; Moro E; Borgo C; Itami K; Hirota T; Pinna LA; Salvi M
    Biochim Biophys Acta Mol Cell Res; 2020 Nov; 1867(11):118807. PubMed ID: 32745724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phellodendrine chloride suppresses proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis.
    Thu PM; Zheng ZG; Zhou YP; Wang YY; Zhang X; Jing D; Cheng HM; Li J; Li P; Xu X
    Eur J Pharmacol; 2019 May; 850():23-34. PubMed ID: 30716311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silmitasertib, a casein kinase 2 inhibitor, induces massive lipid droplet accumulation and nonapoptotic cell death in head and neck cancer cells.
    Su YW; Huang WY; Lin HC; Liao PN; Lin CY; Lin XY; Huang SH; Chen YT; Wu PS
    J Oral Pathol Med; 2023 Mar; 52(3):245-254. PubMed ID: 36273268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual blockade of macropinocytosis and asparagine bioavailability shows synergistic anti-tumor effects on KRAS-mutant colorectal cancer.
    Hanada K; Kawada K; Nishikawa G; Toda K; Maekawa H; Nishikawa Y; Masui H; Hirata W; Okamoto M; Kiyasu Y; Honma S; Ogawa R; Mizuno R; Itatani Y; Miyoshi H; Sasazuki T; Shirasawa S; Taketo MM; Obama K; Sakai Y
    Cancer Lett; 2021 Dec; 522():129-141. PubMed ID: 34543685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis.
    Liu X; Ghosh D
    Int J Nanomedicine; 2019; 14():6589-6600. PubMed ID: 31496700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
    Zheng T; Wang J; Chen X; Meng X; Song X; Lu Z; Jiang H; Liu L
    Tumour Biol; 2010 Aug; 31(4):287-95. PubMed ID: 20422343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.
    Xu L; Hausmann M; Dietmaier W; Kellermeier S; Pesch T; Stieber-Gunckel M; Lippert E; Klebl F; Rogler G
    BMC Cancer; 2010 Jun; 10():302. PubMed ID: 20565817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcription Factor Eb Is Required for Macropinocytosis-Mediated Growth Recovery of Nutrient-Deprived Kras-Mutant Cells.
    Jeong S; Byun JK; Cho SJ; Chin J; Lee IK; Choi YK; Park KG
    Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS
    Hobbs GA; Der CJ
    Subcell Biochem; 2022; 98():205-221. PubMed ID: 35378710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
    Gene; 2019 May; 698():50-60. PubMed ID: 30822475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.
    Colyn L; Alvarez-Sola G; Latasa MU; Uriarte I; Herranz JM; Arechederra M; Vlachogiannis G; Rae C; Pineda-Lucena A; Casadei-Gardini A; Pedica F; Aldrighetti L; López-López A; López-Gonzálvez A; Barbas C; Ciordia S; Van Liempd SM; Falcón-Pérez JM; Urman J; Sangro B; Vicent S; Iraburu MJ; Prosper F; Nelson LJ; Banales JM; Martinez-Chantar ML; Marin JJG; Braconi C; Trautwein C; Corrales FJ; Cubero FJ; Berasain C; Fernandez-Barrena MG; Avila MA
    J Exp Clin Cancer Res; 2022 May; 41(1):183. PubMed ID: 35619118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ubiquitin-binding associated protein 2 regulates KRAS activation and macropinocytosis in pancreatic cancer.
    Xiong X; Rao G; Roy RV; Zhang Y; Means N; Dey A; Tsaliki M; Saha S; Bhattacharyya S; Dhar Dwivedi SK; Rao CV; McCormick DJ; Dhanasekaran D; Ding K; Gillies E; Zhang M; Yang D; Bhattacharya R; Mukherjee P
    FASEB J; 2020 Sep; 34(9):12024-12039. PubMed ID: 32692445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autophagy Induced by CX-4945, a Casein Kinase 2 Inhibitor, Enhances Apoptosis in Pancreatic Cancer Cell Lines.
    Hwang DW; So KS; Kim SC; Park KM; Lee YJ; Kim SW; Choi CM; Rho JK; Choi YJ; Lee JC
    Pancreas; 2017 Apr; 46(4):575-581. PubMed ID: 28196025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macropinocytosis Renders a Subset of Pancreatic Tumor Cells Resistant to mTOR Inhibition.
    Michalopoulou E; Auciello FR; Bulusu V; Strachan D; Campbell AD; Tait-Mulder J; Karim SA; Morton JP; Sansom OJ; Kamphorst JJ
    Cell Rep; 2020 Feb; 30(8):2729-2742.e4. PubMed ID: 32101748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.